Tapewire

NYSE · USD

EW

Edwards Lifesciences Corp

Export transactions ↓
Tapewire entity
3026
SEC CIK
0001099800
Parsed reports
947

Last 12 months

Inside the activity.

0 purchase rows · 54 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202503
Dec 2025010
Jan 202603
Feb 202603
Mar 202604
Apr 202605
May 2026012
Jun 202602
Jul 202604
Aug 202606
Sep 202601
Oct 202601

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
September 01, 2016 Filed Sep 6, 2016 21:16 UTC
MUSSALLEM MICHAEL ADirector · Chairman & CEO
Exercise / conversionCommon Stock 49,100 $25.48 $1,251,068.00
Disclosure

SEC source: 0001225208-16-038850 · doc4.xml · nonDerivative · entry 1

MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,737.82

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 28, 2016.

F2 · balance_after: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.